• 1
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl.):S147S334.
  • 2
    Bousquet J, VanCauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA) – executive summary. Allergy 2002;57:841855.
  • 3
    Lockey RF. ‘ARIA’: global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001;108:497499.
  • 4
    Demoly P, Allaert FA, Lecasble M, Bousquet J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003;58:672675.
  • 5
    Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005;35:728732.
  • 6
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758764.
  • 7
    Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005;60:350353.
  • 8
    Van Hoecke H, Vastesaeger N, Dewulf L, Sys L, Van Cauwenberge P. Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy 2006;61:705711.
  • 9
    Bachert C, Van Cauwenberge P, Olbrecht J, Van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006;61:693698.
  • 10
    International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy 1994;49(Suppl.):134.
  • 11
    Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81:463468.
  • 12
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 1994;94:182188.
  • 13
    Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162:13911396.
  • 14
    Gerth Van Wijk R. Quality of life, should we bother? Allergy 2003;58:284286.
  • 15
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:7783.
  • 16
    Kremer B, Klimek L, Bullinger M, Mosges R. Generic or disease-specific quality of life scales to characterize health status in allergic rhinitis? Allergy 2001;56:957963.
  • 17
    Hornblow AR, Kidson MA. The visual analogue scale for anxiety: a validation study. Aust N Z J Psychiatry 1976;10:339341.
  • 18
    Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:4556.
  • 19
    Simola M, Malmberg H. Sensation of nasal airflow compared with nasal airway resistance in patients with rhinitis. Clin Otolaryngol 1997;22:260262.
  • 20
    Linder A. Symptom scores as measures of the severity of rhinitis. Clin Allergy 1988;18:2937.
  • 21
    Hallen H, Djupesland P, Kramer J, Toll K, Graf P. Evaluation of a new method for assessing symptoms. ORL J Otorhinolaryngol Relat Spec 2001;63:9295.
  • 22
    Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003;58:733741.
  • 23
    Numminen J, Ahtinen M, Huhtala H, Rautiainen M. Comparison of rhinometric measurements methods in intranasal pathology. Rhinology 2003;41:6568.
  • 24
    Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460472.
  • 25
    Herman D, Garay R, Le-Gal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol 1997;39:18.
  • 26
    Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, De Monchy JG, Bruijnzeel-Koomen CA et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003;349:237246.
  • 27
    Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J et al. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol 2003;91:105114.
  • 28
    Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006;117:158162.
  • 29
    Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the rhinoconjunctivitis quality of life questionnaire. J Allergy Clin Immunol 1999;104:364369.
  • 30
    Cox D. The regression analysis of binary sequences. J Roy Stat Soc B Met 1958;20:215242.
  • 31
    McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984;4:137150.
  • 32
    Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989;29:307335.
  • 33
    Song HH. Analysis of correlated ROC areas in diagnostic testing. Biometrics 1997;53:370382.
  • 34
    Anaes. Évaluation et suivi de la douleur chez l'adulte en médecine ambulatoire. Argumentaire. Paris: Publication Anaes, 1999.
  • 35
    Price D. The validation of visual analog scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:4553.
  • 36
    Bateman ED. Severity and control of severe asthma. J Allergy Clin Immunol 2006;117:519521.
  • 37
    Li J, Oppehneimer J, Bernstein I, Nicklas R. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005;116:S3S11.
  • 38
    White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 1998;28:266270.
  • 39
    Juniper EF, Guyatt GH, Streiner DL, King DR. Clinical impact versus factor analysis for quality of life questionnaire construction. J Clin Epidemiol 1997;50:233238.
  • 40
    Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902907.
  • 41
    Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891899.
  • 42
    Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838844.
  • 43
    Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy 2002;57:586591.